ACURA PHARMACEUTICALS, INC 8-K

What Happened

• Acura Pharmaceuticals filed a Form 8-K on June 29, 2026 reporting that it received short-term loans from Abuse Deterrent Pharma, LLC (AD Pharma) of $100,000 on May 15, 2026; $100,000 on May 29, 2026; and $200,000 on June 24, 2026.
• These amounts, together with prior borrowing (including $2,319,279 under the November 10, 2022 amended secured promissory note), bring the Note principal balance to $10,694,279 with accrued interest of approximately $1,160,000 as of June 24, 2026. The Note bears interest at 5.25% (7.5% on overdue amounts after non-payment).

Key Details

• New loans: $100,000 (May 15, 2026), $100,000 (May 29, 2026), $200,000 (June 24, 2026).
• Total principal under the amended secured promissory note: $10,694,279; accrued interest ≈ $1,160,000 (as of June 24, 2026).
• Interest rate: 5.25% per annum; default interest: 7.5% on overdue amounts. Events of default include bankruptcy, missed payments (five-day cure period for some defaults), and inability to pay debts as they become due.
• Use of funds: to meet day-to-day operating needs. The company warned that without additional financing by late July 2026 it may need to scale back operations, furlough or lay off employees, or seek bankruptcy protection.

Why It Matters

• The company is relying on continued financing from AD Pharma and others to cover operating costs; the filing makes clear the financing situation is time-sensitive (late July 2026) and that failure to secure more funds could materially curtail operations or lead to bankruptcy.
• Investors should note the sizeable secured indebtedness and accrued interest, the relatively modest recent loan amounts (totaling $400k), and the higher interest rate that applies on missed payments—factors that increase financial risk until longer-term funding or revenue is secured.